1. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Issue 8 (21st February 2016) Authors: Brandes, Alba A.; Carpentier, Antoine F.; Kesari, Santosh; Sepulveda-Sanchez, Juan M.; Wheeler, Helen R.; Chinot, Olivier; Cher, Lawrence; Steinbach, Joachim P.; Capper, David; Specenier, Pol; Rodon, Jordi; Cleverly, Ann; Smith, Claire; Gueorguieva, Ivelina; Miles, Colin; Guba, Susan C.; Desaiah,... Journal: Neuro-oncology Issue: Volume 18:Issue 8(2016:Aug.) Page Start: 1146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. (November 2021) Authors: Galot, Rachel; Le Tourneau, Christophe; Saada-Bouzid, Esma; Daste, Amaury; Even, Caroline; Debruyne, Philip; Henry, Stéphanie; Zanetta, Sylvie; Rutten, Anemie; Licitra, Lisa; Canon, Jean-Luc; Kaminsky, Marie-Christine; Specenier, Pol; Rottey, Sylvie; Guigay, Joël; Kong, Anthony; Tinhofer, Inge; B... Journal: European journal of cancer Issue: Volume 158(2021) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Afatinib in squamous cell carcinoma of the head and neck. (12th June 2016) Authors: Specenier, Pol; Vermorken, Jan Journal: Expert opinion on pharmacotherapy Issue: Volume 17:Number 9(2016) Page Start: 1295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. An overview of binimetinib for the treatment of melanoma. (2nd May 2020) Authors: Specenier, Pol Journal: Expert opinion on pharmacotherapy Issue: Volume 21:Number 7(2020) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. An overview of binimetinib for the treatment of melanoma. (2nd May 2020) Authors: Specenier, Pol Journal: Expert opinion on pharmacotherapy Issue: Volume 21:Number 7(2020) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Antineoplastic therapy-induced pulmonary toxicity. Issue 8 (August 2013) Authors: Sadowska, Anna M; Specenier, Pol; Germonpre, Paul; Peeters, Marc Journal: Expert review of anticancer therapy Issue: Volume 13:Issue 8(2013) Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Anti‐Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. (2nd July 2013) Authors: Boeckx, Carolien; Baay, Marc; Wouters, An; Specenier, Pol; Vermorken, Jan B.; Peeters, Marc; Lardon, Filip Journal: Oncologist Issue: Volume 18:Number 7(2013) Page Start: 850 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Bevacizumab in glioblastoma multiforme. Issue 1 (January 2012) Authors: Specenier, Pol Journal: Expert review of anticancer therapy Issue: Volume 12:Issue 1(2012) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Bevacizumab in glioblastoma multiforme. Issue 1 (January 2012) Authors: Specenier, Pol Journal: Expert review of anticancer therapy Issue: Volume 12:Issue 1(2012) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Biologic Therapy in Head and Neck Cancer: A Road with Hurdles. (13th June 2012) Authors: Specenier, Pol; Vermorken, Jan B. Other Names: Celetti A. Academic Editor.; Dornfeld K. J. Academic Editor.; Kuhnel F. Academic Editor. Journal: ISRN oncology Issue: Volume 2012(2012) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗